首页> 美国卫生研究院文献>BioMed Research International >Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells
【2h】

Reduction of Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels by Ticlopidine in TNF-α Stimulated Human Umbilical Vein Endothelial Cells

机译:噻氯匹定在TNF-α刺激的人脐静脉内皮细胞中降低单核细胞趋化蛋白-1和白介素8水平

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Atherosclerosis and its associated complications represent major causes of morbidity and mortality in the industrialized or Western countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions. Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF-α-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as compared to TNF-α stimulated alone. Furthermore, the inhibitory effects were neither due to decreased HUVEC viability, nor through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-α induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and prevention of atherosclerosis.
机译:动脉粥样硬化及其相关并发症是工业化或西方国家发病率和死亡率的主要原因。单核细胞趋化蛋白-1(MCP-1)对于动脉粥样硬化病变的发生和发展至关重要。白细胞介素8(IL-8),一种CXC趋化因子,刺激中性粒细胞趋化性。噻氯匹定是用于预防与动脉粥样硬化的病理生理相关的血栓形成的抗血小板药物之一。在这项研究中,我们发现噻氯匹定可剂量依赖性地降低人脐静脉内皮细胞中TNF-α刺激的MCP-1,IL-8和血管细胞粘附分子1(VCAM-1)的mRNA和蛋白水平( HUVEC)。与单独刺激的TNF-α相比,噻氯匹定降低了U937细胞的粘附和趋化性。此外,抑制作用既不是由于HUVEC生存力降低,也不是由于NF-kB抑制。这些结果表明噻氯匹定可降低HUVEC中TNF-α诱导的MCP-1,IL-8和VCAM-1水平,并降低单核细胞粘附。因此,该数据提供了噻氯匹定在治疗和预防动脉粥样硬化中的其他治疗机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号